Two of North America’s leading cancer centers, Moffitt Cancer Center in Tampa, Fla., and The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James), founded and lead what is likely the largest collaboration of its kind to accelerate cancer discovery and deliver hope through collaborative learning and partnerships.
Named the Oncology Research Information Exchange Network (ORIEN), this new partnership among several of America’s top cancer centers launched with over 100,000 consented patients who have agreed to donate their tissue and clinical data for research that will help medical scientists understand cancer at the molecular level. As of February 2016, more than 133,000 patients had consented to join ORIEN.
ORIEN member institutions utilize a single protocol, Total Cancer Care® (TCC), to create a collaborative, “rapid learning” environment that enables them to share de-identified data so they can accelerate the development of targeted treatments and more quickly match eligible patients to clinical trials.
National System Long Overdue
ORIEN’s main goal is to develop more precise ways to prevent, detect, diagnose and treat cancer.
Through data analysis and sharing, ORIEN helps provide physicians and investigators with opportunities to develop the best therapeutic options, including clinical trial treatments that are specific to a patient’s biological and epidemiological profile. This increases the likelihood of treatment efficacy, speeds response time and potentially minimizes side effects while improving outcomes.
Patients are followed throughout their lifetime and can play an active role in the study of their cancer while helping to improve care for future generations.
ORIEN partners utilize TCC as a common protocol that was established by Moffitt in 2006. TCC provides a standard system for tracking patient molecular, clinical and epidemiological data throughout each patient’s lifetime. Partners have access to one of the world’s largest clinically annotated cancer tissue repositories and data from more than 130,000 consenting patients.
M2Gen®, a subsidiary of Moffitt, serves as an operational and commercial provider for support of ORIEN, bringing expertise in data management and informatics.
The ORIEN collaborative currently has 11 members in North America, including the OSUCCC – James and Moffitt, that collectively have volume of more than 50,000 new cancer patients per year.
ORIEN Guiding Principles
- Inclusiveness: Participation by Cancer Centers and patients in their respective communities
- Accessibility of Data: Real-time access to research data through RIE using a hybrid model of both a centralized data warehouse and a federated component: a network model
- Public-Private Partnerships: Establish trusted business relationships within and across sectors to achieve long- term program sustainability
- Collaboration: Commit to using a common protocol to ensure quality and consistency
ORIEN's Common Protocol: Total Cancer Care®
Total Cancer Care® provides a common protocol for all cancer centers to use when consenting new patients.
This protocol follows patients throughout their lifetime to permit sharing of data and information, studies each patient's tumor using molecular technology, and maintains contact with patients.
TCC uses an "opt-in" approach that makes patients active partners in a lifelong study of their disease. Patient consent allows for ongoing use of clinical, molecular, outcome, and self-reported data from patients and their healthcare providers. It enables data to be shared, which promotes a rapid learning environment, matches patients to clinical trials and re-contacts them.
Meeting the Challenge of Drug Development and Clinical Trials
ORIEN’s approach to clinical trial matching also gives pharmaceutical companies an opportunity to modernize trial recruitment and facilitate adaptive clinical trial design. Through M2Gen, researchers can:
- Enroll a high volume of patients in Total Cancer Care® through ORIEN
- Anticipate needs of patients enrolled in TCC by understanding their clinical and molecular properties
- Follow patients over time and track disease progression/recurrence
- Identify patients who qualify for target-based trials
- Rapidly accrue patients to trials at less cost, meeting both patient and pharmaceutical needs
Ultimately, researchers will be better equipped to identify candidates for their drug trials, leading to better outcomes. ORIEN also accelerates and improves efficiencies of clinical trials and the drug-approval process, including post-market surveillance.
For additional information, visit ORIENcancer.org.